Circio Holding ASA Approval and publication of prospectus
Oslo, 12 November 2026: The Financial Supervisory Authority of Norway (Finanstilsynet) has today approved a prospectus for Circio Holding ASA ("Circio" or the "Company"), consisting of a registration document, a securities note and a summary (together, the "Prospectus").
The Prospectus is a listing prospectus only and relates solely to 54,286,869 shares already issued and listed on the Oslo Stock Exchange in connection with the Company's share issuances in February, April, June and September 2026, as described in the Prospectus. No shares are being offered in connection with the Prospectus.
The Prospectus process was initiated in connection with the subsequent offering planned following the private placement of approx. NOK 200 million completed on 14 September 2026. The subsequent offering was cancelled on 23 September 2026. As the process was well advanced, the Company decided to complete the Prospectus. The Prospectus also ensures that the Company can continue to use the exemption in Article 1(5)(a) of the EU Prospectus Regulation.
Subject to applicable securities laws, the Prospectus will be made available on the Company's website, www.circio.com (https://eur03.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.circio.com%2F&data=05|02|mats.hermansen%40circio.com|1f9a83e4875e4940a9e908df3c133da3|66b0661a3ec348a8a9665b0cce82b3fe|0|0|639295725456187481|Unknown|TWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D|0|||&sdata=ygmhVVuwB6NE2dNXehS1VjEaPpuVRU9pAEFCnr85tvY%3D&reserved=0), under "Investors".
This announcement is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities.
For further information, please contact: Erik Digman Wiklund, CEO Phone: +47 413 33 536 Email: erik.wiklund@circio.com
Lubor Gaal, CFO Phone: +34 683 34 3811 Email: lubor.gaal@circio.com
About Circio Building circular RNA expression systems for enhanced gene and cell therapies
Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.
Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 60-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.